Brooklyn, New York 11203

  • Parkinson's Disease


The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.


Main Inclusion Criteria: - Idiopathic Parkinson's disease for at least 5 years - Presence of motor fluctuations and dyskinesia - Stable regimen of levodopa/carbidopa for 30 days - At least 25% response/improvement in UPDRS part III scores after dosing with regular PD medications - MMSE score of 25 or higher Main Exclusion Criteria: - Atypical or secondary parkinsonism. - Prior use of neuroleptic agents. - History of intracranial procedures for PD. - Active psychosis. - History of drug or alcohol abuse in past 12 months. - Cardiac conduction system abnormality. - Predisposing medical condition that causes nausea or vomiting or routine use of an anti-emetic.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

Official Title:

Overall Status:


Study Phase:

Phase 2



Minimum Age:

40 Years

Maximum Age:

85 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Asubio Pharmaceuticals, Inc.

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Study Dates

Start Date:April 2007
Completion Date:July 2008
Completion Type:Actual
Primary Completion Date:July 2008
Primary Completion Type:Actual
Verification Date:April 2011
Last Changed Date:April 4, 2011
First Received Date:January 2, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:"on" time without dyskinesia
Time Frame:48 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Safety and tolerability data as measured by adverse events, electrocardiograms, physical exams, clinical laboratories tests, and vital signs
Time Frame:48 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:pharmacokinetic data for investigational study drug
Time Frame:48 hours
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:piclozotan, IV
Arm Name:piclozotan
Intervention Type:Drug
Name:0.9% sodium chloride (normal saline)
Description:0.9% sodium chloride (normal saline)
Arm Name:0.9 % sodium chloride (normal saline)

Study Arms

Study Arm Type:Placebo Comparator
Arm Name:0.9 % sodium chloride (normal saline)
Study Arm Type:Active Comparator
Arm Name:piclozotan

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Asubio Pharmaceuticals, Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.